Publications by authors named "R E Lacroix"
Tissue factor (TF) is a transmembrane protein essential for hemostasis. Different forms of active TF circulate in the blood, either as a component of blood cells and extracellular vesicles (EVs) or as a soluble plasma protein. Accumulating experimental and clinical evidence suggests that TF plays an important role in thrombosis.
View Article and Find Full Text PDFSelecting and raising dairy animals that are more likely to reach their potential is a strategy to increase milk production efficiency and overall profitability. However, indicators are necessary for the early identification of animals that are less likely to perform well, allowing for their early culling and ensuring that resources are allocated to those with the highest potential. The objective of this study was to analyze the association between early-life animal health and performance with longevity, production, and profitability.
View Article and Find Full Text PDFArticle Synopsis
- The thrombomodulin (TM) variant c.1611C>A causes the production of a truncated protein (TM536) lacking a cytoplasmic tail and with a shorter transmembrane domain, but little is known about how it is released from cells.
- Research using different endothelial cells showed that TM536 is released through a unique mechanism involving its insertion into the endoplasmic reticulum, where it escapes and enters the typical secretory pathway without being broken down.
- This abnormal release process leads to a soluble TM536 that is less effective at performing its role in activating protein C and is also retained in the early secretory pathway, making it more susceptible to degradation and reducing its presence on the cell surface
Background: Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19, or cancer.
View Article and Find Full Text PDFBackground: Understanding current substance use practices is critical to reduce and prevent overdose deaths among individuals at increased risk including persons who use and inject drugs. Because individuals participating in harm reduction and syringe service programs are actively using drugs and vary in treatment participation, information on their current drug use and preferred drugs provides a unique window into the drug use ecology of communities that can inform future intervention services and treatment provision.
Methods: Between March and June 2023, 150 participants in a harm reduction program in Burlington, Vermont completed a survey examining sociodemographics; treatment and medication for opioid use disorder (MOUD) status; substance use; injection information; overdose information; and mental health, medical, and health information.